Silexion Therapeutics Reveals Promising Preclinical Data for SIL204

The latest announcement is out from Silexion Therapeutics ( (SLXN) ).

On July 31, 2025, Silexion Therapeutics announced new preclinical data demonstrating SIL204’s significant efficacy in inhibiting cancer cell growth, with up to 97% inhibition in pancreatic cancer cells and nearly 90% in colorectal cancer cells. The findings reveal SIL204’s potential as a pan-KRAS therapeutic, showing unprecedented inhibition rates against previously untested KRAS mutations, and positioning the company for a Phase 2/3 clinical trial in 2026, which could impact its market positioning and provide new treatment options for KRAS-driven cancers.

The most recent analyst rating on (SLXN) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, which are the most common oncogenic drivers in human cancers. The company is advancing its next-generation siRNA candidate, SIL204, and has shown promising results in preclinical studies, particularly in targeting a broader range of KRAS mutations.

Average Trading Volume: 48,680

Technical Sentiment Signal: Sell

Current Market Cap: $7.19M

See more data about SLXN stock on TipRanks’ Stock Analysis page.